Title
Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design
UMMS Affiliation
Department of Biochemistry and Molecular Pharmacology
Publication Date
2014-05-02
Document Type
Article
Subjects
Alcohol Oxidoreductases; Amino Acid Motifs; Catalytic Domain; Crystallography, X-Ray; DNA-Binding Proteins; Drug Design; Enzyme Inhibitors; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Methionine; Models, Molecular; Nerve Tissue Proteins; Protein Binding
Disciplines
Biochemistry | Biochemistry, Biophysics, and Structural Biology | Medicinal-Pharmaceutical Chemistry | Molecular Biology
Abstract
The oncogenic corepressors C-terminal Binding Protein (CtBP) 1 and 2 harbor regulatory d-isomer specific 2-hydroxyacid dehydrogenase (d2-HDH) domains. 4-Methylthio 2-oxobutyric acid (MTOB) exhibits substrate inhibition and can interfere with CtBP oncogenic activity in cell culture and mice. Crystal structures of human CtBP1 and CtBP2 in complex with MTOB and NAD(+) revealed two key features: a conserved tryptophan that likely contributes to substrate specificity and a hydrophilic cavity that links MTOB with an NAD(+) phosphate. Neither feature is present in other d2-HDH enzymes. These structures thus offer key opportunities for the development of highly selective anti-neoplastic CtBP inhibitors. Elsevier B.V. All rights reserved.
DOI of Published Version
10.1016/j.febslet.2014.03.026
Source
FEBS Lett. 2014 May 2;588(9):1743-8. doi: 10.1016/j.febslet.2014.03.026. Epub 2014 Mar 19. Link to article on publisher's site
Journal/Book/Conference Title
FEBS letters
Related Resources
PubMed ID
24657618
Repository Citation
Hilbert BJ, Grossman SR, Schiffer CA, Royer WE. (2014). Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design. Biochemistry and Molecular Biotechnology Publications. https://doi.org/10.1016/j.febslet.2014.03.026. Retrieved from https://escholarship.umassmed.edu/bmp_pp/206
Comments
First author Brendan Hilbert is a doctoral student in the Biochemistry and Molecular Pharmacology program in the Graduate School of Biomedical Sciences (GSBS) at UMass Medical School.